Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.8047
-0.1680 (-17.27%)
At close: Apr 1, 2025, 4:00 PM
0.9704
+0.1657 (20.60%)
After-hours: Apr 1, 2025, 4:02 PM EDT
Barinthus Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 110.66 | 142.09 | 194.39 | 214.05 | 43.27 | Upgrade
|
| Cash & Short-Term Investments | 110.66 | 142.09 | 194.39 | 214.05 | 43.27 | Upgrade
|
| Cash Growth | -22.12% | -26.90% | -9.19% | 394.74% | 278.46% | Upgrade
|
| Accounts Receivable | - | - | 5.85 | 0.02 | 0.52 | Upgrade
|
| Other Receivables | 7.14 | 7.94 | 6.31 | 6.93 | 3.01 | Upgrade
|
| Receivables | 7.14 | 7.94 | 12.16 | 6.95 | 3.53 | Upgrade
|
| Prepaid Expenses | 5.86 | 5.4 | 5.89 | 4.61 | 1.08 | Upgrade
|
| Restricted Cash | 1.74 | - | - | - | - | Upgrade
|
| Other Current Assets | 0.34 | 1.47 | 0.61 | 1.15 | 0.03 | Upgrade
|
| Total Current Assets | 125.74 | 156.91 | 213.04 | 226.77 | 47.9 | Upgrade
|
| Property, Plant & Equipment | 11.76 | 19.4 | 15.71 | 9.09 | 2.77 | Upgrade
|
| Goodwill | - | 12.21 | 12.21 | 12.63 | - | Upgrade
|
| Other Intangible Assets | 21.95 | 25.11 | 28.27 | 31.43 | - | Upgrade
|
| Other Long-Term Assets | 0.88 | 0.88 | 0.98 | 0.8 | - | Upgrade
|
| Total Assets | 160.33 | 214.51 | 270.21 | 280.72 | 50.67 | Upgrade
|
| Accounts Payable | 2.47 | 1.6 | 3.75 | 2.42 | 4.67 | Upgrade
|
| Accrued Expenses | 9.53 | 9.21 | 8.06 | 7.88 | 2.54 | Upgrade
|
| Short-Term Debt | - | - | - | 0.16 | - | Upgrade
|
| Current Portion of Leases | 1.92 | 1.79 | 0.43 | 0.52 | 0.19 | Upgrade
|
| Current Unearned Revenue | 1.74 | - | - | 0.18 | 0.25 | Upgrade
|
| Total Current Liabilities | 15.66 | 12.6 | 12.24 | 11.16 | 7.64 | Upgrade
|
| Long-Term Debt | - | - | - | - | 44.7 | Upgrade
|
| Long-Term Leases | 10.09 | 11.19 | 8.34 | 6.54 | 1.47 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.44 | 0.57 | 3.75 | 8.08 | - | Upgrade
|
| Other Long-Term Liabilities | 4.01 | 3.15 | 2.68 | 2.37 | - | Upgrade
|
| Total Liabilities | 30.19 | 27.51 | 27 | 28.15 | 53.81 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 393.47 | 386.6 | 379.5 | 369.1 | 21.66 | Upgrade
|
| Retained Earnings | -237.66 | -176.59 | -103.24 | -108.59 | -57.72 | Upgrade
|
| Comprehensive Income & Other | -25.78 | -23.23 | -33.37 | -8.39 | -1.24 | Upgrade
|
| Total Common Equity | 130.03 | 186.78 | 242.9 | 252.13 | -37.3 | Upgrade
|
| Minority Interest | 0.11 | 0.21 | 0.31 | 0.44 | 0.39 | Upgrade
|
| Shareholders' Equity | 130.14 | 187 | 243.2 | 252.56 | -3.15 | Upgrade
|
| Total Liabilities & Equity | 160.33 | 214.51 | 270.21 | 280.72 | 50.67 | Upgrade
|
| Total Debt | 12.01 | 12.98 | 8.77 | 7.22 | 46.36 | Upgrade
|
| Net Cash (Debt) | 98.66 | 129.11 | 185.61 | 206.83 | -3.1 | Upgrade
|
| Net Cash Growth | -23.59% | -30.44% | -10.26% | - | - | Upgrade
|
| Net Cash Per Share | 2.51 | 3.36 | 4.86 | 7.99 | -0.39 | Upgrade
|
| Filing Date Shares Outstanding | 40.34 | 38.92 | 38.34 | 37.19 | 0.03 | Upgrade
|
| Total Common Shares Outstanding | 40.23 | 38.64 | 37.68 | 37.19 | 0.03 | Upgrade
|
| Working Capital | 110.09 | 144.31 | 200.8 | 215.61 | 40.26 | Upgrade
|
| Book Value Per Share | 3.23 | 4.83 | 6.45 | 6.78 | -1447.99 | Upgrade
|
| Tangible Book Value | 108.08 | 149.47 | 202.42 | 208.07 | -37.3 | Upgrade
|
| Tangible Book Value Per Share | 2.69 | 3.87 | 5.37 | 5.59 | -1447.99 | Upgrade
|
| Machinery | 7.51 | 6.84 | 5.35 | 2.09 | 1.06 | Upgrade
|
| Leasehold Improvements | 9.28 | 8.67 | 3.93 | 0.63 | 0.05 | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.